electroCore Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

electroCore şirketinin toplam hissedar öz sermayesi $11.8M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $18.3M ve $6.5M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$11.91m
Eşitlik	US$11.85m
Toplam yükümlülükler	US$6.45m
Toplam varlıklar	US$18.30m

Son finansal sağlık güncellemeleri

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 43E0 'nin kısa vadeli varlıkları ( $15.4M ) kısa vadeli yükümlülüklerini ( $5.8M ) aşıyor.

Uzun Vadeli Yükümlülükler: 43E0 şirketinin kısa vadeli varlıkları ( $15.4M ) uzun vadeli yükümlülüklerini ( $605.0K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 43E0 borçsuzdur.

Borcun Azaltılması: 43E0 un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 43E0 son raporlanan serbest nakit akışına göre 8 ay boyunca yeterli nakit pistine sahiptir, ancak o zamandan beri ek sermaye artırmıştır.

Tahmini Nakit Akışı: 43E0 serbest nakit akışı tahminlerine göre 9 ay boyunca yeterli nakit akışına sahip olması öngörülüyor, ancak o zamandan beri ek sermaye artırdı.

electroCore Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

electroCore Receives a Determination Letter from Nasdaq Regarding Minimum Bid Price

electroCore Announces Listing Transfer to the Nasdaq Capital Market

Recent updates

electroCore, Inc. to Report Q3, 2024 Results on Nov 13, 2024

electroCore, Inc. to Report Q2, 2024 Results on Aug 07, 2024

electroCore, Inc., Annual General Meeting, Sep 03, 2024

electroCore Announces the Commercial Launch of TAC-STIM™?

electroCore, Inc. has completed a Derivatives Offering in the amount of $1.446525 million.

electroCore, Inc. announced a financing transaction

electroCore, Inc. Appoints Donald Melnikoff as SVP, Engineering, Regulatory, and Compliance

electroCore, Inc. to Report Q1, 2024 Results on May 08, 2024

electroCore, Inc. Announces Results of Truvaga Plus Consumer Study

electroCore, Inc. Announces the Launch of Truvaga Plus® for General Wellness

electroCore, Inc. to Report Q4, 2023 Results on Mar 13, 2024

electroCore, Inc. Appoints Charles S. Theofilos as New Class Iii Member of the Board

Electrocore, Inc. Announces Data Highlighting Non-Invasive Vagus Nerve Stimulation (Nvns) for Treatment of Symptoms of Gastroparesis

electroCore, Inc. to Report Q3, 2023 Results on Nov 08, 2023

electroCore, Inc. Announces the Publication of Two Peer Reviewed Publication of Two Peer Reviewed Publications Supporting the Use of Gammacore ( Non-Invasive Vagus Nerve Stimulation; nVNS) in Patients with Post Traumatic Stress Disorder

electroCore, Inc. Announces Dismissal of All Litigation Related to Its 2018 Initial Public Offering

electroCore, Inc. Reiterates Revenue Guidance for the Year 2023

electroCore, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Electrocore Provides Earnings Guidance for the Second Quarter and Full Fiscal Year 2023

electroCore, Inc., Annual General Meeting, Aug 04, 2023

electroCore, Inc. Reiterates Revenue Guidance for the Year Ending December 31, 2023

electroCore, Inc. Provides Preliminary Earnings Guidance for the Fourth Quarter and Full Year of 2022

electroCore Receives a Determination Letter from Nasdaq Regarding Minimum Bid Price

electroCore, Inc. Launches New Wellness Product Offering for Stress, Anxiety and Sleep, Truvaga

electroCore, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

electroCore, Inc. to Report Q3, 2022 Results on Nov 03, 2022

electroCore, Inc. Provides Revenue Guidance for the Third Quarter of 2022

electroCore, Inc., Annual General Meeting, Dec 02, 2022

electroCore, Inc. Announces Publication of a Peer Reviewed Manuscript, Transcutaneous Cervical Vagus Nerve Stimulation Reduces Behavioral and Physiological Manifestations of Withdrawal in Patients with Opioid Use Disorder

electroCore, Inc. Provides Revenue Guidance for the Third Quarter of 2022

electroCore, Inc. to Report Q2, 2022 Results on Aug 04, 2022

electroCore, Inc. Provides Preliminary Unaudited Earnings Guidance for the Second Quarter of 2022

Electrocore, Inc. Announces Study of Gammacore Sapphire™ for the Treatment of Post-Covid Syndrome

electroCore Announces Listing Transfer to the Nasdaq Capital Market

Co-Founder recently bought €53k worth of stock

Electrocore, Inc. Announces Gammacore™ Non-Invasive Vagus Nerve Stimulator Available Through National Spine and Pain Centers

Electrocore, Inc. Announces Gammacore™ Non-Invasive Vagus Nerve Stimulator Available Through National Spine and Pain Centers

First quarter 2022 earnings released: US$0.079 loss per share (vs US$0.11 loss in 1Q 2021)

electroCore, Inc. Provides Earnings Guidance for the Second Quarter of 2022

High number of new directors

electroCore Announces Publication of Investigator-Initiated Trial Data for SAVIOR-1 in COVID-19 Patients in Frontiers in Neurology

electroCore, Inc. Provides Unaudited Preliminary Revenue Guidance for the First Quarter of 2022

High number of new directors

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

electroCore, Inc. to Report Q4, 2021 Results on Mar 10, 2022

electroCore, Inc. Announces Completion of Enrollment in the TRANSIT Study of non-Invasive Vagus Nerve Stimulation (nVNS) in Post-Operative Ileus

electroCore, Inc. Provides Revenue Guidance for the Full Year of 2021

electroCore, Inc. Announces Publication of Premium II Trial of Gammacore (Non-Invasive Vagus Nerve Stimulation; nVNS) for the Prevention of Migraine

Third quarter 2021 earnings released: US$0.057 loss per share (vs US$0.10 loss in 3Q 2020)

electroCore Announces 510(k) Clearance of gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) to Treat Paroxysmal Hemicrania and Hemicrania Continua

Second quarter 2021 earnings released: US$0.06 loss per share (vs US$0.13 loss in 2Q 2020)

electroCore, Inc. Announces Revenue Guidance for the Second Quarter of 2021

electroCore, Inc. has completed a Follow-on Equity Offering in the amount of $18 million.

electroCore, Inc. Announces Publication of Study on Non-Invasive Vagus Nerve Stimulation (nVNS) to Improve Clinical Outcomes and Molecular Biomarkers in Parkinson’S Disease Patients

electroCore, Inc. Develops Non-Drug and Non-Invasive Alternative to Pharmaceuticals That Safely and Effectively Stimulates the Vagus Nerve to Communicate with the Brain and Help Optimize the Body’s Own Ability to Control Problems Impacting Its Health

First quarter 2021 earnings released: US$0.11 loss per share (vs US$0.27 loss in 1Q 2020)

electroCore, Inc. Provides Earnings Guidance for the Second Quarter of 2021

electroCore, Inc. Announces Johns Hopkins University School of Medicine Study of Non-Invasive Vagus Nerve Stimulation (nVNS) for Symptomatic Exacerbation of Nausea in Patients with Gastroparesis and Related Disorders

ElectroCore, Inc. Provides Revenue Guidance for the First Quarter of 2020

Full year 2020 earnings released: US$0.60 loss per share (vs US$1.54 loss in FY 2019)

electroCore, Inc. to Report Q4, 2020 Results on Mar 11, 2021

electroCore, Inc. Announces Exclusive Distribution Agreement with Medistar2 PTY Limited Following Regulatory Approval in Australia

Non-Invasive Vagus Nerve Stimulation (Nvns) Enters New Stage of Covid-19 Research of electrocore, Inc

electroCore Announces 510(k) Clearance of gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) to Treat Adolescent Migraine

electroCore, Inc. Announces Completion of Enrollment in SAVIOR-1 Study of Non-Invasive Vagus Nerve Stimulation (nVNS) in COVID-19 Patients Exhibiting Respiratory Symptoms

New 90-day high: €2.50

Electrocore Announces Publication of Study on Non-Invasive Vagus Nerve Stimulation (Nvns) to Reduce Ileus After Major Colorectal Surgery

electroCore Announces Full Enrollment of TR-VENUS study of Non-Invasive Vagal Nerve Stimulation (nVNS) for the Acute Treatment of Stroke

electroCore, Inc. Announces Exclusive Distribution Agreement with RSK Medical Inc. in Canada

New 90-day high: €1.60

New 90-day low: €1.16

electroCore, Inc. Announces Agreement with Pro Medical Baltic to be Exclusive Distributor for gammaCore Sapphire™ in Eastern Europe

electroCore Announces Selection of gammaCore for National Institute on Drug Abuse (NIDA)-Sponsored Study in Opioid Use Disorders